H.C. Wainwright analyst Jason Kolbert maintained a Buy rating on Keryx Biopharma (NASDAQ: KERX) today and set a price target of $9. The company’s shares closed yesterday at $3.32, close to its 52-week low of $2.93.
Kolbert commented:
“Our therapeutic models are patient-based and reflect our assumptions for the market size and share penetration rates and pricing. We use this to determine the future revenue streams. These metrics then flow into our valuation model.”
According to TipRanks.com, Kolbert is ranked 0 out of 5 stars with an average return of -4.1% and a 37.3% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Cytori Therapeutics Inc, Anavex Life Sciences, and Can-Fite BioPharma.
Keryx Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $8.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.07 and a one-year low of $2.93. Currently, Keryx Biopharma has an average volume of 1.13M.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. Most recently, in June 2018, Kevin J. Cameron, a Director at KERX bought 10,000 shares for a total of $4,800.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Keryx Biopharmaceuticals, Inc. engages in the manufacture, development, and commercialization of medicines for use in treating human diseases. Its product is the Auryxia tablet. The company was founded in October 1998 and is headquartered in Boston, MA.
